Minh-Phuong Huynh-Le1, Amanda J Walker1, Peter C Burger2, George I Jallo3, Kenneth J Cohen4, Moody D Wharam1, Stephanie A Terezakis5. 1. Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, 401 N. Broadway, Suite 1440, Baltimore, MD, 21287, USA. 2. Department of Pathology, Johns Hopkins Hospital, Baltimore, MD, 21231, USA. 3. Department of Neurological Surgery, Johns Hopkins Hospital, Baltimore, MD, 21231, USA. 4. Division of Pediatric Oncology, Johns Hopkins Hospital, Baltimore, MD, 21231, USA. 5. Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, 401 N. Broadway, Suite 1440, Baltimore, MD, 21287, USA. Sterezak@jhmi.edu.
Abstract
INTRODUCTION: The treatment of pediatric intracranial low-grade gliomas (LGG) generally begins with maximal safe resection. Radiation therapy (RT) and chemotherapy are typically reserved for patients with incomplete resection and/or disease progression. We report long-term treatment outcomes and toxicities in a cohort of pediatric patients with LGG after RT. METHODS: Thirty-four patients <21 years old with intracranial LGG who were treated with RT at the Johns Hopkins Hospital were included in this retrospective analysis. Patients were evaluated for overall survival (OS), progression-free survival (PFS), recurrence patterns, and treatment toxicities using descriptive statistics, Kaplan-Meier curves, and Cox proportional hazard regressions. RESULTS: The mean age at diagnosis was 7.9 years (range 1.2-18.3 years) and mean age at RT was 9.8 years (range 3.0-28.9 years). The median follow-up time was 9.8 years after radiation (range 0.8-33.3 years). The estimated 10-year OS and PFS after RT were 92 and 74 %, respectively. Twelve patients had disease progression after RT, and all recurrences were local. Two patients died due to disease progression 2.3 and 9.1 years after RT. One patient had malignant transformation of LGG to high-grade glioma. No significant predictors of PFS were identified on uni- or multivariate analysis. Late effects of LGG and treatment seen were endocrine deficiencies in 16 patients, visual problems in 10 patients, hearing loss in 4 patients, special education requirements for 5 patients, and a vascular injury/demyelination secondary to RT in 1 patient. CONCLUSION: Our study suggests that the use of radiation in patients with intracranial LGG results in excellent OS and PFS with acceptable toxicity at long-term follow-up.
INTRODUCTION: The treatment of pediatric intracranial low-grade gliomas (LGG) generally begins with maximal safe resection. Radiation therapy (RT) and chemotherapy are typically reserved for patients with incomplete resection and/or disease progression. We report long-term treatment outcomes and toxicities in a cohort of pediatric patients with LGG after RT. METHODS: Thirty-four patients <21 years old with intracranial LGG who were treated with RT at the Johns Hopkins Hospital were included in this retrospective analysis. Patients were evaluated for overall survival (OS), progression-free survival (PFS), recurrence patterns, and treatment toxicities using descriptive statistics, Kaplan-Meier curves, and Cox proportional hazard regressions. RESULTS: The mean age at diagnosis was 7.9 years (range 1.2-18.3 years) and mean age at RT was 9.8 years (range 3.0-28.9 years). The median follow-up time was 9.8 years after radiation (range 0.8-33.3 years). The estimated 10-year OS and PFS after RT were 92 and 74 %, respectively. Twelve patients had disease progression after RT, and all recurrences were local. Two patients died due to disease progression 2.3 and 9.1 years after RT. One patient had malignant transformation of LGG to high-grade glioma. No significant predictors of PFS were identified on uni- or multivariate analysis. Late effects of LGG and treatment seen were endocrine deficiencies in 16 patients, visual problems in 10 patients, hearing loss in 4 patients, special education requirements for 5 patients, and a vascular injury/demyelination secondary to RT in 1 patient. CONCLUSION: Our study suggests that the use of radiation in patients with intracranial LGG results in excellent OS and PFS with acceptable toxicity at long-term follow-up.
Entities:
Keywords:
Low-grade gliomas; Pediatrics; Radiation therapy; Surgery
Authors: R Brauner; F Malandry; R Rappaport; J M Zucker; C Kalifa; A Pierre-Kahn; P Bataini; J L Dufier Journal: Eur J Pediatr Date: 1990-09 Impact factor: 3.183
Authors: K Müller; A Gnekow; F Falkenstein; J Scheiderbauer; I Zwiener; T Pietsch; M Warmuth-Metz; J Voges; G Nikkhah; M Flentje; S E Combs; D Vordermark; M Kocher; R-D Kortmann Journal: Strahlenther Onkol Date: 2013-07-07 Impact factor: 3.621
Authors: Femke K Aarsen; Philippe F Paquier; Roel E Reddingius; Isabelle C Streng; Willem-Frans M Arts; Marjon Evera-Preesman; Coriene E Catsman-Berrevoets Journal: Cancer Date: 2006-01-15 Impact factor: 6.860
Authors: Rolf-Dieter Kortmann; Beate Timmermann; Roger E Taylor; Giovanni Scarzello; Ludwig Plasswilm; Frank Paulsen; Branislav Jeremic; Astrid K Gnekow; Karin Dieckmann; Sylvia Kay; Michael Bamberg Journal: Strahlenther Onkol Date: 2003-08 Impact factor: 3.621
Authors: Kavita K Mishra; Dev R Puri; Brian T Missett; Kathleen R Lamborn; Michael D Prados; Mitchel S Berger; Anuradha Banerjee; Nalin Gupta; William M Wara; Daphne A Haas-Kogan Journal: Neuro Oncol Date: 2006-02-22 Impact factor: 12.300
Authors: R D Chadderton; C G West; S Schuller; D C Quirke; R Gattamaneni; R Taylor; S Schulz Journal: Childs Nerv Syst Date: 1995-08 Impact factor: 1.475
Authors: Thomas E Merchant; Heather M Conklin; Shengjie Wu; Robert H Lustig; Xiaoping Xiong Journal: J Clin Oncol Date: 2009-07-06 Impact factor: 44.544
Authors: Rolf-Dieter Kortmann; Beate Timmermann; Roger E Taylor; Giovanni Scarzello; Ludwig Plasswilm; Frank Paulsen; Branislav Jeremic; Astrid K Gnekow; Karin Dieckmann; Sylvia Kay; Michael Bamberg Journal: Strahlenther Onkol Date: 2003-09 Impact factor: 3.621
Authors: Anthony P Y Liu; Camden Hastings; Shengjie Wu; Johnnie K Bass; Andrew M Heitzer; Jason Ashford; Robert Vestal; Mary E Hoehn; Yahya Ghazwani; Sahaja Acharya; Heather M Conklin; Frederick Boop; Thomas E Merchant; Amar Gajjar; Ibrahim Qaddoumi Journal: Cancer Date: 2019-01-08 Impact factor: 6.860
Authors: Joel M Cherlow; Dennis W W Shaw; Linda R Margraf; Daniel C Bowers; Jie Huang; Maryam Fouladi; Arzu Onar-Thomas; Tianni Zhou; Ian F Pollack; Amar Gajjar; Sandy K Kessel; Patricia L Cullen; Kevin McMullen; John C Wellons; Thomas E Merchant Journal: Int J Radiat Oncol Biol Phys Date: 2018-11-10 Impact factor: 7.038
Authors: Shervin Tabrizi; Beow Y Yeap; Janet C Sherman; Lisa B Nachtigall; Mary K Colvin; Michael Dworkin; Barbara C Fullerton; Juliane Daartz; Trevor J Royce; Kevin S Oh; Tracy T Batchelor; William T Curry; Jay S Loeffler; Helen A Shih Journal: Radiother Oncol Date: 2019-05-10 Impact factor: 6.280
Authors: Jeanelle S Ali; Jason M Ashford; Michelle A Swain; Lana L Harder; Bonnie L Carlson-Green; Jonathan M Miller; Joanna Wallace; Ryan J Kaner; Catherine A Billups; Arzu Onar-Thomas; Thomas E Merchant; Amar Gajjar; Heather M Conklin Journal: J Clin Oncol Date: 2021-05-04 Impact factor: 50.717
Authors: Nataliya Zhukova; Revathi Rajagopal; Adrienne Lam; Lee Coleman; Peter Shipman; Thomas Walwyn; Molly Williams; Michael Sullivan; Martin Campbell; Kanika Bhatia; Nicholas G Gottardo; Jordan R Hansford Journal: Cancer Med Date: 2018-12-19 Impact factor: 4.452